We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Aurora Cannabis Stock: What Organigram's Buyout Means for Investors
Read MoreHide Full Article
Key Takeaways
Aurora shares jumped over 22% after Organigram agreed to acquire the company for C$561 million.
Organigram's C$7.80-per-share offer represents a 93% premium to Aurora's unaffected share price.
The deal could generate over C$50 million in annual synergies, but Curaleaf's rival bid remains outstanding.
Aurora Cannabis (ACB - Free Report) was back in the spotlight, thanks to a new twist in the takeover battle surrounding the cannabis producer.
Shares of the company jumped more than 22% on Tuesday after Canada-based cannabis producer Organigram Global (OGI - Free Report) agreed to acquire Aurora in a deal valued at about C$561 million (~$400 million).
The deal comes after Aurora rejected Curaleaf Holdings’ (CURLF - Free Report) hostile takeover offer, making Organigram's proposal a new development for investors weighing the company's takeover prospects. Unlike the CURLF deal that was rejected by ACB, the OGI deal has been approved by ACB’s board of directors.
Organigram's Buyout Offer: What's on the Table?
Per the new agreement, Organigram will acquire all outstanding Aurora shares for C$7.80 per share, valuing the company at approximately C$561 million on a fully diluted equity basis. The offer represents a 93% premium to Aurora's unaffected share price on Aug. 10, before Curaleaf's takeover approach became public. It also represents a 21% premium to Curaleaf's revised offer, which was announced on Oct. 6.
Curaleaf proposed US$1 in cash and 0.4013 Curaleaf shares for each ACB share, implying an implied value of US$5 per share at the time. In comparison, Organigram offers Aurora shareholders three payment options — C$7.80 in cash per share, 5.8626 OGI shares for each ACB share, or a combination of C$3.75 in cash and 3.0431 OGI shares.
However, both the all-cash and all-share elections are subject to proration. If shareholder elections exceed the respective cash or share allocations available under the agreement, investors may receive a different mix of cash and shares than they originally requested. The combination option offers a middle ground, allowing shareholders to realize a portion of their investment in cash while retaining exposure to the combined company's growth potential.
The cash option offers a fixed payment if the transaction closes, while the value of the stock-based alternatives will fluctuate with Organigram's share price. For ACB shareholders, the proposed deal provides a clear exit value after months of takeover uncertainty, although the final consideration will depend on the applicable election and proration.
Why Could the OGI Deal Benefit ACB Shareholders?
Per the companies, the proposed acquisition could create a stronger cannabis business by combining Aurora's international medical cannabis operations with Organigram's established recreational cannabis business in Canada. Aurora has built a presence across key international markets, including Europe, Australia and New Zealand, supported by its EU-GMP-certified production facilities. In contrast, Organigram brings a portfolio of Canadian recreational cannabis brands, production capabilities and research expertise, along with its European presence through Sanity Group.
The companies expect the combination to generate more than C$50 million in annual cost synergies, which could improve operating efficiency and profitability over time. The combined business is also expected to operate five EU-GMP-certified production and distribution facilities, strengthening its ability to serve international medical cannabis markets.
The transaction will also receive financial backing from British American Tobacco (“BAT”), which has agreed to invest C$187.5 million in Organigram through a concurrent private placement. The investment is intended to help fund the cash consideration and transaction expenses. Aurora shareholders who receive OGI shares will also retain an ownership interest in the combined company, which is expected to represent approximately 35% of its economic ownership and 42% of its voting rights.
For ACB investors, the deal offers not only a premium to Aurora's unaffected share price but also the opportunity to participate in a larger cannabis business with potential cost savings and broader market reach.
ACB Stock Performance & Valuation
Year to date, shares of Aurora have gained over 22% against the industry‘s 17% decline.
Image Source: Zacks Investment Research
Estimate movements for fiscal 2026 and 2027 have remained constant in the past 30 days.
Image Source: Zacks Investment Research
Our Take
Despite unanimous board support, the Organigram transaction is not yet a done deal. It remains subject to Aurora shareholder approval and regulatory clearances, with closing expected in January 2027. Until then, ACB shareholders remain exposed to execution risk. Moreover, any delay or failure to complete the deal could put some of the recent share-price gains at risk.
There is also a question of how much control shareholders will have over the form of consideration they ultimately receive. The all-cash and all-share elections under the Organigram agreement are subject to proration, meaning investors may not receive their preferred mix in full if the respective allocation limits are exceeded. Those receiving OGI shares will also remain exposed to fluctuations in stock price until and after closing. Consequently, while the C$7.80 offer provides a proposed transaction value, it does not eliminate all uncertainty around the timing or final value shareholders receive.
Curaleaf also adds another layer of uncertainty. Its revised hostile bid remains outstanding, and on Nov. 3, the company reiterated that it believes its offer represents better value. Curaleaf said it would review the OGI proposal and is seeking further details on matters including the break fee, future management and board composition, and BAT's investor rights. While Curaleaf has not announced a new offer, the possibility of a renewed bidding contest remains. Curaleaf's October revision included a provision allowing the maximum consideration to rise to US$6 per ACB share under certain conditions, giving it room to improve its proposal.
Against this backdrop, Aurora's Zacks Rank #3 (Hold) suggests a more balanced near-term outlook, rather than a strong buy or sell signal. The rank reflects the current earnings-estimate picture, while the stock's performance may continue to be influenced by developments surrounding the takeover proposals. Investors may therefore want to weigh the potential for a higher competing bid against the conditions attached to the OGI deal.
View the Zacks #1 Rank List
Image: Bigstock
Aurora Cannabis Stock: What Organigram's Buyout Means for Investors
Key Takeaways
Aurora Cannabis (ACB - Free Report) was back in the spotlight, thanks to a new twist in the takeover battle surrounding the cannabis producer.
Shares of the company jumped more than 22% on Tuesday after Canada-based cannabis producer Organigram Global (OGI - Free Report) agreed to acquire Aurora in a deal valued at about C$561 million (~$400 million).
The deal comes after Aurora rejected Curaleaf Holdings’ (CURLF - Free Report) hostile takeover offer, making Organigram's proposal a new development for investors weighing the company's takeover prospects. Unlike the CURLF deal that was rejected by ACB, the OGI deal has been approved by ACB’s board of directors.
Organigram's Buyout Offer: What's on the Table?
Per the new agreement, Organigram will acquire all outstanding Aurora shares for C$7.80 per share, valuing the company at approximately C$561 million on a fully diluted equity basis. The offer represents a 93% premium to Aurora's unaffected share price on Aug. 10, before Curaleaf's takeover approach became public. It also represents a 21% premium to Curaleaf's revised offer, which was announced on Oct. 6.
Curaleaf proposed US$1 in cash and 0.4013 Curaleaf shares for each ACB share, implying an implied value of US$5 per share at the time. In comparison, Organigram offers Aurora shareholders three payment options — C$7.80 in cash per share, 5.8626 OGI shares for each ACB share, or a combination of C$3.75 in cash and 3.0431 OGI shares.
However, both the all-cash and all-share elections are subject to proration. If shareholder elections exceed the respective cash or share allocations available under the agreement, investors may receive a different mix of cash and shares than they originally requested. The combination option offers a middle ground, allowing shareholders to realize a portion of their investment in cash while retaining exposure to the combined company's growth potential.
The cash option offers a fixed payment if the transaction closes, while the value of the stock-based alternatives will fluctuate with Organigram's share price. For ACB shareholders, the proposed deal provides a clear exit value after months of takeover uncertainty, although the final consideration will depend on the applicable election and proration.
Why Could the OGI Deal Benefit ACB Shareholders?
Per the companies, the proposed acquisition could create a stronger cannabis business by combining Aurora's international medical cannabis operations with Organigram's established recreational cannabis business in Canada. Aurora has built a presence across key international markets, including Europe, Australia and New Zealand, supported by its EU-GMP-certified production facilities. In contrast, Organigram brings a portfolio of Canadian recreational cannabis brands, production capabilities and research expertise, along with its European presence through Sanity Group.
The companies expect the combination to generate more than C$50 million in annual cost synergies, which could improve operating efficiency and profitability over time. The combined business is also expected to operate five EU-GMP-certified production and distribution facilities, strengthening its ability to serve international medical cannabis markets.
The transaction will also receive financial backing from British American Tobacco (“BAT”), which has agreed to invest C$187.5 million in Organigram through a concurrent private placement. The investment is intended to help fund the cash consideration and transaction expenses. Aurora shareholders who receive OGI shares will also retain an ownership interest in the combined company, which is expected to represent approximately 35% of its economic ownership and 42% of its voting rights.
For ACB investors, the deal offers not only a premium to Aurora's unaffected share price but also the opportunity to participate in a larger cannabis business with potential cost savings and broader market reach.
ACB Stock Performance & Valuation
Year to date, shares of Aurora have gained over 22% against the industry‘s 17% decline.
Image Source: Zacks Investment Research
Estimate movements for fiscal 2026 and 2027 have remained constant in the past 30 days.
Image Source: Zacks Investment Research
Our Take
Despite unanimous board support, the Organigram transaction is not yet a done deal. It remains subject to Aurora shareholder approval and regulatory clearances, with closing expected in January 2027. Until then, ACB shareholders remain exposed to execution risk. Moreover, any delay or failure to complete the deal could put some of the recent share-price gains at risk.
There is also a question of how much control shareholders will have over the form of consideration they ultimately receive. The all-cash and all-share elections under the Organigram agreement are subject to proration, meaning investors may not receive their preferred mix in full if the respective allocation limits are exceeded. Those receiving OGI shares will also remain exposed to fluctuations in stock price until and after closing. Consequently, while the C$7.80 offer provides a proposed transaction value, it does not eliminate all uncertainty around the timing or final value shareholders receive.
Curaleaf also adds another layer of uncertainty. Its revised hostile bid remains outstanding, and on Nov. 3, the company reiterated that it believes its offer represents better value. Curaleaf said it would review the OGI proposal and is seeking further details on matters including the break fee, future management and board composition, and BAT's investor rights. While Curaleaf has not announced a new offer, the possibility of a renewed bidding contest remains. Curaleaf's October revision included a provision allowing the maximum consideration to rise to US$6 per ACB share under certain conditions, giving it room to improve its proposal.
Against this backdrop, Aurora's Zacks Rank #3 (Hold) suggests a more balanced near-term outlook, rather than a strong buy or sell signal. The rank reflects the current earnings-estimate picture, while the stock's performance may continue to be influenced by developments surrounding the takeover proposals. Investors may therefore want to weigh the potential for a higher competing bid against the conditions attached to the OGI deal.
You can see the complete list of today’s Zacks #1 Rank stocks here.